Diabetic nephropathy (DN) is a major healthcare challenge. It occurs in up to 50% of those
living with diabetes, is a major cause of end‐stage kidney disease (ESKD) that requires …

Biomarker development, improvement, and clinical implementation in the context of kidney
disease have been a central focus of biomedical research for decades. To this point, only …

OBJECTIVE Persons with diabetes but no chronic kidney disease (CKD) and without
albuminuria have the same age-related decline in kidney function as the background …

Introduction: Metabolomics could offer novel prognostic biomarkers and elucidate
mechanisms of diabetic kidney disease (DKD) progression. Via metabolomic analysis of …

Background & aim Previous studies have explored the relation of metabolic syndrome
(MetS), its components and the risk of albuminuria/proteinuria but their results are …

Background The urinary proteomic classifier CKD273 has shown promise for prediction of
progressive diabetic nephropathy (DN). Whether it is also a determinant of mortality and …

Aims To determine among adolescents and young adults with youth-onset type 1 diabetes
and type 2 diabetes the rates and risk factors for albuminuria regression and progression …

Background: Chronic kidney disease (CKD) risk is elevated in patients with type 2 diabetes
mellitus (T2DM). Disease management in these patients has been generally focused on …

Effective management of chronic kidney disease (CKD), a major health problem worldwide,
requires accurate and timely diagnosis, prognosis of progression, assessment of therapeutic …

The mineralocorticoid receptor antagonist spironolactone significantly reduces albuminuria
in subjects with diabetic kidney disease, albeit with a large variability between individuals …